Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.
Shanghai Pharmaceuticals Holding Co., Ltd. announced an equity adjustment involving the transfer of the entire equity interest in Shanghai Industrial Investment (Holdings) Company Limited to Golden Bell International Holdings Limited. This adjustment increases the shareholding of Shanghai Shangshi (Group) Co., Ltd. from 25.303% to 38.487% without changing the company’s controlling shareholder or de facto controller, which remains Shanghai SASAC. The adjustment complies with relevant regulations, exempting the acquirer from a mandatory tender offer, and does not trigger any mandatory general offer obligations under Hong Kong’s Code on Takeovers and Mergers.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in China, operating within the pharmaceutical industry. It focuses on industrial investment, domestic trade, and the management of state-owned assets, with a significant market presence in China.
Average Trading Volume: 3,875,371
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$77.63B
Find detailed analytics on 2607 stock on TipRanks’ Stock Analysis page.